Atara Preclinical Pipeline Expanding with Novel Technology Collaborations

Program
Indication
Target
Technologies
Collaborator
ATA2321
AML
Dual-targeted undisclosed
Novel CAR T co-stimulation domains(1)
Moffitt Cancer Center
ATA2431
B-cell malignancies
Multi-targeted CD19-CD20-CD22
Novel CAR T co-stimulation domains(1)
Moffitt Cancer Center
ATA3219
B-cell malignancies
CD19
Novel CAR T co-stimulation domain
Atara program
Other CAR T Program
Solid tumors
Undisclosed
CAR T PD-1 DNR;
Novel CAR T co-stimulation domain
Memorial Sloan Kettering Cancer Center
Other CAR T Program
Autoimmune disease
Undisclosed
Novel CAR T co-stimulation domain
Memorial Sloan Kettering Cancer Center
Other CAR T Program
Infectious disease
Undisclosed
Novel CAR T co-stimulation domain
Memorial Sloan Kettering Cancer Center
ATA621
JCV PML and BKVAN
BK/JCV
Selective viral antigen targeting
ATA368
HPV associated cancers
HPV
Selective viral antigen targeting

PD-1 DNR: Programmed Death receptor-1 Dominant Negative Receptor (1) Development expected to start in autologous setting

Learn more about Atara’s next generation CAR T technologies and collaborator publications & presentations